Find policies, billing codes, payers, states, and providers
CPT 78815: PET/CT Tumor Imaging for Anatomical Localization
CPT code 78815 represents PET imaging with a concurrently acquired CT used for attenuation correction and anatomical localization of tumors. This hybrid imaging study merges metabolic PET data with CT anatomy to support tumor detection, staging, and treatment planning, making it a critical tool in oncology diagnostics and care pathways nationwide. Payers commonly covering this service in analyses include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
Readers will find a concise overview of the code’s clinical role, the typical sites of service where PET/CT is performed, and how this modality fits into cancer care workflows. The publication provides benchmarking context across major payers, explains common clinical indications and associated ICD-10 diagnosis examples, and compares related CPT codes for limited-area and whole-body PET/CT imaging. Policy and billing notes summarize coverage considerations and coding relationships relevant to radiology and nuclear medicine practices.
This material is intended to support revenue cycle staff, clinical leaders, and policy analysts seeking a national perspective on the use and categorization of PET/CT tumor imaging under CPT code 78815.
Customize your policy alerts
Sign up for cpt 78815 policy alerts
Get alerted when payer policies referencing 78815 are released or updated.
Monitor payer policy activity
Billing Code Overview
CPT code 78815 describes a combined positron emission tomography (PET) scan with concurrently acquired computed tomography (CT) used for attenuation correction and anatomical localization of tumors. The procedure fuses metabolic information from PET with anatomical detail from CT to improve tumor detection, staging, and treatment planning.
-
Service type: Diagnostic tumor imaging combining PET and CT for anatomical localization and metabolic assessment
-
Typical site of service: Outpatient imaging centers or hospital radiology departments where PET/CT systems are available
National Reimbursement Benchmarks
Medicare’s mean allowed rate of $112.3 is far below the commercial average represented by BUCA’s mean of $2,026.20, underscoring a wide gulf between government reimbursement and typical commercial contracts for CPT 78815. This gap reflects fundamentally different pricing benchmarks: Medicare’s tightly clustered local rates (p25 $108, p50 $112, p75 $114) contrast with BUCA’s substantially higher central tendency (p50 $1,824.30) and broader spread across commercial payers.
Measuring dispersion as P75 minus P25, Blue Cross Blue Shield shows one of the narrowest interquartile spreads at $1,310.30 (p75 $3,252.40 minus p25 $1,942.10), while UnitedHealth Group’s spread is $1,887.10 (p75 $2,150.60 minus p25 $263.90). Cigna’s IQR is $1,241.60, Aetna’s is $1,082.20, and BUCA’s IQR is $1,342.50; Medicare is the tightest with an IQR of $6.00. These differences highlight greater variability among commercial payers compared with Medicare.